The IGHA1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the HeLa cervical epithelial line, engineered to disrupt the IGHA1 gene. IGHA1 encodes the constant region of the immunoglobulin alpha-1 heavy chain, a core component of secretory IgA. This knockout model provides a null background for investigating IgA1 biology, receptor interactions, and signaling pathways in an epithelial context without the complexities of lymphoid differentiation. The polyclonal nature ensures a representative range of editing events while maintaining genetic heterogeneity.
HeLa cells, an immortalized cell line from a cervical adenocarcinoma, are extensively used in biomedical research due to their rapid growth, ease of genetic manipulation, and well-annotated genome. Although they do not express immunoglobulins, their epithelial origin makes them suitable for studying IgA1?Cepithelium interactions, including transcytosis via the polymeric immunoglobulin receptor and signaling events relevant to mucosal immunity.
The IGHA1 product participates in mucosal immune responses as the constant region of IgA1, which dimerizes with the J chain and binds secretory component for epithelial transcytosis. Upstream, class switch recombination to IgA1 is driven by cytokines TGF-?? and IL-10 through activation-induced cytidine deaminase (AID) downstream of BAFF/APRIL receptors BAFF-R and TACI, involving NF-??B and STAT3/STAT6 transcription factors. The IgA1 constant region engages Fc??RI (CD89) to mediate antibody-dependent cellular cytotoxicity and phagocytosis. In IgA nephropathy, IGHA1 complexes interact with MCAM on mesangial cells, contributing to pathogenesis.
In HeLa cells, IGHA1 knockout eliminates IgA1 heavy chain expression, creating a defined system to study IgA1?Creceptor binding (e.g., CD89, pIgR) and upstream regulators like TGF-?? and IL-10 without interference from B cell-specific factors. This model is particularly useful for antibody engineering, enabling expression and analysis of recombinant IgA1 variants on a null background for structure?Cfunction studies of the constant region.
Key applications include mucosal immunology, IgA nephropathy modeling, host?Cpathogen interactions, and therapeutic antibody research. Researchers can validate knockout by RT-qPCR and Western blotting, localize IgA1 variants via immunofluorescence, quantify secreted IgA1 by ELISA when paired with a variable region, and assess CD89 binding by flow cytometry. The polyclonal population supports robust and reproducible experimental designs. For further product details, contact Ascent Research.
